Trius Therapeutics Raises $20 Million

Trius Therapeutics Inc., a San Diego-based developer of antibacterial drugs for the treatment of serious infections, has raised $20 million in Series A funding. Sofinnova Ventures led the deal, and was joined by InterWest Partners, Prism VentureWorks and Versant Ventures. The company previously was known as Rx3 Pharmaceuticals. www.triusrx.com